Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-life studies and randomized clinical trials: systematic review with metanalysis.
To estimate the frequency of patients achieving MDA status in real-life studies and RCTs. a systematic literature search from 2009-2017 was performed in Pubmed, Embase, Cochrane Library and Lilacs. Study selection and data extraction were performed by two independent researchers. Random effects single-arm meta-analyses were performed and heterogeneity was assessed using I2. 405 records were identified, 45 studies were analyzed: 39 (86.7%) observational studies and 6 RCTs (13.3%); they included 12,469 patients. The overall prevalence of MDA in cross-sectional studies was 35% (95%CI 30-41%, I2=94%), varying from 17% (95%CI 7-34%) in patients taking sDMARDs to 57% (95%CI 41- 71%) in those on bDMARDs. Prevalence of MDA in cohort studies increased with longer follow-up time, ranging from 25% (95%CI 15-40%) with a 3-4 months follow up to 42% (95%CI 38-45) with > 24 months follow-up. PsA patients receiving bDMARDs in real-life context and RCTs had similar prevalence of MDA at 6 months follow-up: 30% (95%CI 21-41%, I2=85%) versus 32% (95% CI 26-39%, I2=79%), respectively. PsA patients included in real-life studies published in the last years have similar prevalence of MDA than those participating in controlled clinical trials. This finding suggests that MDA is a useful treatment target for PsA in the real-life context.